MedTrace Logo

Persistent Atrial Fibrillation (AF) APAC (Asia Pacific) Observational Study

NCT04244396 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2024-04-19

Study results available
· View outcomes & findings →

Summary

The objective of this clinical trial is to collect safety and effectiveness data for the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the APAC patient population for the treatment of drug refractory, symptomatic persistent atrial fibrillation when following standard electrophysiology mapping and radiofrequency (RF) ablation procedures.

Conditions

  • Persistent Atrial Fibrillation

Interventions

DEVICE

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)

TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Kristin Ruffner · Abbott

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-25
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • Hong Kong
  • Singapore
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04244396 on ClinicalTrials.gov